-
Recent Posts
- Dementia-Friendly Communities Provision, Viewed as a Social Determinant of Health (JGCR / NHS England / WHO)
- International Perspectives on the Possible Impact of the COVID-19 Pandemic and Lockdown on Abuse of the Elderly (JGCR / American Journal of Geriatric Psychiatry / JAGS)
- Updates Relating to the Lancet Commission on Dementia Prevention, Intervention, and Care (Lancet / Alzheimer’s Research and Therapy / Alzheimer’s and Dementia)
- A Brief Review of How the COVID-19 Pandemic Relates to Elderly Care and Research (JGCR)
- Some Speculated / Potential Benefits of COVID-19 (JGCR / BBC Radio 4’s Rethink / BGS)
Archives
- September 2020
- August 2020
- June 2020
- April 2020
- March 2020
- February 2020
- January 2020
- December 2019
- November 2019
- October 2019
- September 2019
- August 2019
- July 2019
- June 2019
- May 2019
- April 2019
- March 2019
- February 2019
- January 2019
- December 2018
- November 2018
- October 2018
- September 2018
- August 2018
- July 2018
- June 2018
- May 2018
- April 2018
- March 2018
- February 2018
- January 2018
- December 2017
- November 2017
- October 2017
- September 2017
- August 2017
- July 2017
- June 2017
- May 2017
- April 2017
- March 2017
- February 2017
- January 2017
- December 2016
- November 2016
- October 2016
- September 2016
- August 2016
- July 2016
- June 2016
- May 2016
- April 2016
- March 2016
- February 2016
- January 2016
- December 2015
- November 2015
- October 2015
- September 2015
- August 2015
- July 2015
- June 2015
- May 2015
- April 2015
- March 2015
- February 2015
- January 2015
- December 2014
- November 2014
- October 2014
- September 2014
- August 2014
- July 2014
- June 2014
- May 2014
- April 2014
- March 2014
- February 2014
- January 2014
- December 2013
- November 2013
- October 2013
- September 2013
- August 2013
- July 2013
- June 2013
- May 2013
- April 2013
- March 2013
- February 2013
- January 2013
- December 2012
- November 2012
- October 2012
- September 2012
- August 2012
- July 2012
- June 2012
- May 2012
- April 2012
- March 2012
- February 2012
- January 2012
- December 2011
- November 2011
- October 2011
- September 2011
- August 2011
- July 2011
- June 2011
- May 2011
- April 2011
- March 2011
- February 2011
- January 2011
- December 2010
- November 2010
Categories
- Antipsychotics
- Assistive Technology
- Charitable Bodies
- Commissioning
- Delirium
- Depression
- Enhancing the Healing Environment
- Falls
- Falls Prevention
- Guidelines
- Hip Fractures
- Housing
- Hypertension
- In the News
- Integrated Care
- International
- Local Interest
- Mental Health
- Models of Dementia Care
- National
- ADASS
- All-Party Parliamentary Group (APPG) on Dementia
- BSI
- CQC: Care Quality Commission
- Department of Health
- Department of Health and Social Care (DHSC)
- Health Education England (HEE)
- Housing LIN
- MAGDR
- Mental Health Foundation
- Mental Health Network (NHS Confederation)
- MHP Health Mandate
- National Audit Office
- National Voices
- NEoLCIN
- NEoLCP
- NHS
- NHS Alliance
- NHS Confederation
- NHS Employers
- NHS England
- NHS Evidence
- NHS Improvement
- NICE Guidelines
- NIHR
- NIHRSDO
- Northern Ireland
- Patients Association
- Public Health England
- RCN
- Royal College of Physicians
- Royal College of Psychiatrists
- SCIE
- Scotland
- UK
- UK NSC
- Wales
- Non-Pharmacological Treatments
- Nutrition
- Pain
- Parkinson's Disease
- Patient Care Pathway
- Person-Centred Care
- Personalisation
- Pharmacological Treatments
- Proposed for Next Newsletter
- Quick Insights
- Standards
- Statistics
- Stroke
- Systematic Reviews
- Telecare
- Telehealth
- Universal Interest
Google Translate (100+ Languages)
Tag Archives: Quetiapine
Review of Non-Pharmacological Interventions for Dementia-Related Agitation: Including a Brief Analysis of the Risks and Benefits of Drug Treatments (Translational Psychiatry)
Summary A recently published literature review evaluates the best available evidence on the effectiveness of various non-pharmacological interventions for reducing dementia-related agitation. The author also briefly addresses current viewpoints on balancing the risks and benefits of pharmacotherapy in the management … Continue reading →
Posted in Acute Hospitals, Antipsychotics, For Carers (mostly), For Doctors (mostly), For Nurses and Therapists (mostly), For Researchers (mostly), Local Interest, Management of Condition, Mental Health, Models of Dementia Care, New Cross Hospital, Non-Pharmacological Treatments, Person-Centred Care, Personalisation, Pharmacological Treatments, Quick Insights, Royal Wolverhampton NHS Trust, Royal Wolverhampton NHS Trust Authorial Affiliation, Systematic Reviews, UK, Universal Interest, Wolverhampton
|
Tagged ACADIA Pharmaceuticals, Agitation, Agitation and Aggression, Alternatives to Antipsychotic Drugs, Animal Assisted Therapy, Antipsychotics, Antipsychotics and Risk of Venous Thromboembolism, Antipsychotics in Elderly People with Dementia, Antipsychotics Limitation in Dementia, Antipsychotics-Related Mortality Risks, Aromatherapy, Arts and Music in Dementia, Atypical Antipsychotics, Avanir Pharmaceuticals Inc (California), Behavioural Alternatives to Antipsychotic Drugs, Behavioural and Psychological Symptoms of Dementia (BPSD), Behavioural Problems, Behavioural Problems in People With Dementia, Behavioural Variant Frontotemporal Dementia (bvFTD), BPSD, BPSD: Behavioral and Psychological Symptoms of Dementia, Carbamazepine, Citalopram, Citalopram for Agitation in Alzheimer's Disease: CitAD Trial, Cognitive Behavioral Therapy, Dementia-Related Agitation, Department of Medicine: Royal Wolverhampton NHS Trust, Describe Investigate Create and Evaluate (DICE) Approach, East Kent Hospitals University NHS Foundation Trust, Electroconvulsive Therapy for Agitation and Aggression in Dementia, Improving the Quality of Life for People With Dementia, Interventions for BPSD, Intra-Cellular Therapies, Medication-Related Risks, Medications: Best Usage, Medicines Optimisation, Memantine, Mirtazapine, Mood Disturbances, Multisensory Stimulation, Music Therapy, Music Therapy for BPSD, Music-Based Therapeutic Interventions, Nature Publishing Group, Neuroleptic Discontinuation, Neuroleptics, Neuropsychiatric Symptoms (NPS), Neuropsychiatric Symptoms in People With Dementia, Non-Pharmacological Management of Symptoms, Non-Pharmacological Treatments, Otsuka Pharmaceuticals Limited, Pharmacological Treatments, Potential Harms of Antipsychotic Use, Potentially Inappropriate Medications (PIM), Potentially Inappropriate Prescribing (PIP), Potentially Inappropriate Prescribing in Advanced Dementia, Prescribing of Antipsychotic Drugs For People With Dementia, Quetiapine, Reducing Inappropriate Use of Antipsychotics in Dementia, Risperidone, Simulated Presence Therapy (SPT), Simulated Presence Therapy for BPSD, Targeted Interdisciplinary Model for Evaluation and Treatment of Neuropsychiatric Symptoms (TIME), Translational Psychiatry, Withdrawal of Neuroleptic Medications
|
Leave a comment
Historic Reduction in the Use of Antipsychotics for BPSD in UK General Practice? (Drug Safety)
Summary Data from 111,346 patients with dementia but without a concomitant diagnosis of psychosis indicates that prescribing of certain categories of antipsychotic drugs did reduce from 8.9% in 2001 to 1.4% in 2014. At face value, this reduction in inappropriate … Continue reading →
Posted in Antipsychotics, Commissioning, Community Care, For Carers (mostly), For Doctors (mostly), For Nurses and Therapists (mostly), For Researchers (mostly), For Social Workers (mostly), Management of Condition, Mental Health, Models of Dementia Care, National, NICE Guidelines, Person-Centred Care, Pharmacological Treatments, Quick Insights, Standards, Statistics, UK
|
Tagged Alistair Burns: NHS England’s National Clinical Director for Dementia, Alistair Burns: NHS England’s National Clinical Director for Older People’s Mental Health, Alistair Burns: Professor of Old Age Psychiatry at University of Manchester, Alternatives to Antipsychotic Drugs, Alternatives to Antipsychotic Medication, Amisulpride, Antipsychotic Drugs, Antipsychotic Prescribing in Primary Care, Antipsychotics, Antipsychotics and Risk of Venous Thromboembolism, Antipsychotics in Elderly People with Dementia, Antipsychotics Limitation in Dementia, Antipsychotics-Related Mortality Risks, Atypical Antipsychotics, Avoidable Harm, Avoidable Mortality, Behavioural and Psychological Symptoms of Dementia (BPSD), Centre for Health Informatics: University of Manchester, Centre for Pharmacoepidemiology and Drug Safety: University of Manchester, Centre for Primary Care (University of Manchester), Clinical Practice Research Datalink (CPRD), Discontinuation of Antipsychotics, Division of Informatics Imaging and Data Sciences: University of Manchester, Division of Neuroscience and Experimental Psychology: University of Manchester, Division of Pharmacy and Optometry: University of Manchester, Division of Population Health Health Services Research and Primary Care: University of Manchester, Division of Primary Care: University of Manchester, Division of Psychology and Mental Health: University of Manchester, Drug Safety (Journal), English National Dementia Strategy, First-Generation Antipsychotic Drugs, General Practice, Inappropriate Use of Antipsychotics in Dementia, Longitudinal Changes in Inappropriate Prescribing, Manchester, Manchester Academic Health Sciences Centre, MHRA Committee for the Safety of Medicines, National Dementia Challenge, National Dementia Strategy, National Institute for Health Research Greater Manchester Primary Care Patient Safety Translational Research Centre: University of Manchester, Neuroleptic Discontinuation, Neuroleptics, Olanzapine, Potential Harms of Antipsychotic Use, Prescribing of Antipsychotic Drugs For People With Dementia, Prevalence of Potentially Inappropriate Prescribing of Antipsychotic Drugs, Prime Minister’s Dementia Challenge, Professor Alistair Burns, Psychological Symptoms of Dementia (BPSD), Queen's Medical Centre: University of Nottingham, Quetiapine, Reducing Antipsychotic Prescriptions in Dementia, Reducing Inappropriate Use of Antipsychotics in Dementia, Risperidone, School of Biological Sciences: University of Manchester, School of Health Sciences: University of Manchester, School of Medicine: University of Nottingham, Second-Generation Antipsychotic Drugs, Temporal Changes in Prescribing of Antipsychotic Drugs from 2001 to 2014, University of Manchester, University of Nottingham, Use of Antipsychotics for BPSD in UK General Practice
|
Leave a comment
Introducing the Journal of Geriatric Care and Research (JGCR)
Summary The Journal of Geriatric Care and Research (ISSN 2397-5628) is a recently launched, locally edited, multi-disciplinary peer-reviewed international journal, which covers topics of relevance to the care of the elderly. Concerning Guidelines on the Use of Antipsychotics for Agitation … Continue reading →
Posted in Acute Hospitals, Antipsychotics, Community Care, For Doctors (mostly), For Nurses and Therapists (mostly), For Researchers (mostly), Guidelines, International, Local Interest, Management of Condition, Mental Health, Models of Dementia Care, Person-Centred Care, Pharmacological Treatments, Quick Insights, Wales, Wolverhampton
|
Tagged Academia.edu, Adverse Drug Reactions (ADRs), Adverse Drug Reactions in the Elderly, Adverse Effects, Aggression, Aggressive Behaviour, Agitation, Agitation and Aggression, Alternatives to Antipsychotics, Alzheimer’s Disease-Related Agitation, American Journal of Psychiatry, American Psychiatric Association (APA), American Psychiatric Association: Practice Guideline on the Use of Antipsychotics to Treat Agitation or Psychosis in Patients With Dementia (2016), Antipsychotic Drugs, Antipsychotics, Antipsychotics and Risk of Venous Thromboembolism, Antipsychotics Limitation in Dementia, Antipsychotics Side Effects, Antipsychotics-Related Mortality Risks, Antipsychotics: Neuroleptic Sensitivity, APA Practice Guidelines, Aripiprazole, Atypical Antipsychotics, Avoidable Harm, Avoidable Hospital Mortality, Avoidable Mortality, Behavioural and Psychological Symptoms of Dementia (BPSD), Benefits and Risks of Antipsychotic Treatment, Betsi Cadwaladr University Health Board, Black Country, Black Country Partnership NHS Foundation Trust, BPSD, BPSD: Behavioral and Psychological Symptoms of Dementia, British Indian Psychiatric Association (BIPA), Community and Mental Health Trusts, Dr Sarmishtha Bhattacharyya: Consultant in Old Age Psychiatry at Wrexham Maelor Hospital, Faculty of Health and Social Care: University of Chester, Geriatric Care and Research Organisation (GeriCaRe), Haloperidol, Improving Prescribing Practice, Inappropriate Prescribing, Inappropriate Use of Antipsychotics in Dementia, Journal of Geriatric Care and Research (JGCR), Learning Disabilities, Medication Reviews, Mental Health Trusts, North Wales, Olanzapine, Over-Medication, Over-Medication for People With Learning Disabilities, Over-Prescribing, Overprescribing, People With Learning Disabilities, Personalised Care Versus Guideline-Based Care, Personalised Medicine Versus Guideline-Based Medicine, Potential Harms of Antipsychotic Use, Potentially Inappropriate Prescribing, Prescribing Anti-Psychotic Drugs to People with Dementia, Prescribing of Antipsychotic Drugs For People With Dementia, Prescribing of Antipsychotic Drugs For People With Learning Disabilities, Psychosis in Patients With Dementia, Quetiapine, Reducing Agitation and Distress, Reducing Antipsychotic Prescriptions in Dementia, Reducing Avoidable Premature Mortality, Reducing Inappropriate Use of Antipsychotics, Reducing Inappropriate Use of Antipsychotics in Dementia, Reducing Violence and Aggression, Risperidone, Safe and Compassionate Care, United States, University of Chester, USA, Violence and Aggression, West Midlands, Wrexham, Wrexham Maelor Hospital, Ziprasidone
|
Leave a comment
Dementia Revealed: Dementia Guide / Toolkit for GPs (NHS England / Department of Health / RCGP)
Summary NHS England has a commitment to improve dementia diagnosis rates. NHS England has published a guide to help GPs perform better on the timely diagnosis of dementia and to offer advice on post-diagnostic support for the person with the … Continue reading →
Posted in Alzheimer's Society, Antipsychotics, Charitable Bodies, Commissioning, Community Care, Delirium, Department of Health, Diagnosis, End of Life Care, Falls, For Doctors (mostly), For Nurses and Therapists (mostly), For Researchers (mostly), For Social Workers (mostly), Integrated Care, Management of Condition, Mental Health, Models of Dementia Care, National, NHS, NHS England, Non-Pharmacological Treatments, Patient Care Pathway, Person-Centred Care, Pharmacological Treatments, Practical Advice, Quick Insights, Standards, UK, Universal Interest
|
Tagged 4AT Score, 4AT Screening Instrument for Rapid Initial Assessment of Delirium and Cognitive Impairment, Abbreviated Mental Test Score (AMTS), ACE III: Modified Addenbrooke’s Test, Activities of Daily Living (ADLs), Acute Change or Fluctuating Course, Addenbrooke's Cognitive Examination (ACE), Advance Decision to Refuse Treatment (ADRT), Advance Directives, Agitation, Alcohol Consumption, Alcohol Misuse, Alistair Burns: NHS England’s National Clinical Director for Dementia, Alternatives to Medication for Agitation, AMT4 (Abbreviated Mental Test - 4), Anticholinergic Drugs, Anticholinergics, Antipsychotics Limitation in Dementia, Antipsychotics: Neuroleptic Sensitivity, AT4 (Delirium Scale), Behavioural and Psychological Symptoms of Dementia (BPSD), Benefits Advice, Benzodiazepines, BPSD, BPSD: Behavioral and Psychological Symptoms of Dementia, Care Homes, Caregiver Assessments, Carers' Assessments, Clomethiazole, Coding of Dementia, Cognitive Stimulation Therapy (CST), Dementia and Alcohol, Dementia and Driving Guidance, Dementia Coding, Dementia Diagnosis Rates, Dementia Prevalence Calculator, Dementia Revealed: Dementia Guide for GPs, Dementia Toolkit for GP Commissioners, Dementia Toolkit for GPs, Deprivation of Liberty Safeguards (DoLS), Diagnosis and Assessment, Diagnosis and Referral, Diagnosis and Support, Diagnosis at Primary Care Level, Dr Elizabeth Barrett: Shires Health Care (Hardwick CCG), Driving, Driving and Dementia, Early Diagnosis, Fluctuation Assessment Scales, Fluctuations, General Practice, General Practice in England, General Practices, General Practitioner Assessment of Cognition (GPCOG), Geriatric Depression Scale, GPCog (The General Practitioner assessment of Cognition), GPs' Dementia Toolkit, IMCAs and Safeguarding, Improving Coding, Improving Dementia Diagnosis Rates, Improving General Practice, Inappropriate Use of Antipsychotics in Dementia, Independent Mental Capacity Advocates (IMCAs), Lasting Power of Attorney (LPoA), Lorazepam, Low Dose Antipsychotics, Managing Agitation, Memantine, Memory Clinics, Mini Mental State Examination (MMSE), Mirtazapine, Montreal Cognition Assessment (MOCA), NHS Continuing Care, NHS Hardwick CCG, Post-Diagnosis Support, Post-Diagnostic Support, Primary Care, Professor Alistair Burns, Quetiapine, RCGP, Risperidone, Rivastigmine, Royal College of General Practitioners (RCGP), Safeguarding Vulnerable Adults, Sertraline, Shires Health Care, Simon Stevens: Chief Executive of NHS England (2014-), Social Services, Support for Improving Dementia Diagnosis Rates, Temazepam, Timely Diagnosis, Trazodone, Voluntary Organisations, Wernicke-Korsakoff Syndrome, Zopiclone
|
Leave a comment
Reducing Antipsychotic Drugs in Care Homes (Nursing Times)
Summary A recent Nursing Times articles covers the use of antipsychotic drugs for people with dementia living in care homes. It discusses a review by pharmacists which resulted in the use of these drugs being reduced or discontinued. It covers … Continue reading →
Posted in Antipsychotics, Community Care, For Carers (mostly), For Doctors (mostly), For Nurses and Therapists (mostly), For Researchers (mostly), For Social Workers (mostly), Integrated Care, Management of Condition, Mental Health, Models of Dementia Care, National, Patient Care Pathway, Person-Centred Care, Pharmacological Treatments, Practical Advice, Quick Insights, RCN, Standards, UK, Universal Interest
|
Tagged Alternatives to Antipsychotic Medication, AntiCholinergic Burden Scale, Anticholinergic Discontinuation, Anticholinergic Drugs, Anticholinergics, Antipsychotic Drugs, Antipsychotic Prescribing in Care Homes, Antipsychotic Prescribing in Nursing Homes, Antipsychotics Side Effects, Antipsychotics-Related Mortality Risks, Atypical Antipsychotics, Behavioural and Psychological Symptoms of Dementia (BPSD), Boots Care Services, Boots UK, BPSD, BPSD: Behavioral and Psychological Symptoms of Dementia, Care Homes, Differemtial Antipsychotic-Related Mortality Risks, Differential Risk of Death (Antipsychotic Drugs), Inappropriate Use of Antipsychotics in Dementia, Managing Medicines in Care Homes, Nursing Times, Quetiapine, Reducing Antipsychotic Drugs in Care Homes, Reducing Antipsychotic Medication in Care Homes, Reducing Inappropriate Use of Antipsychotics in Dementia, School of Pharmacy: University of East Anglia, University of East Anglia
|
Leave a comment
Antipsychotics for the Management of Agitation in Adults with Personality Disorders or Cognitive Impairment (CADTH)
Summary This Canadian Agency for Drugs and Technologies in Health (CADTH) report summarises existing guidelines and reviews on the clinical effectiveness of antipsychotics for reducing agitation in adults with personality disorders or cognitive impairment. Full Text Link Reference Antipsychotics for … Continue reading →
Posted in Acute Hospitals, Antipsychotics, Community Care, For Doctors (mostly), For Researchers (mostly), International, Management of Condition, Pharmacological Treatments, Quick Insights, Standards, Systematic Reviews
|
Tagged Aggression, Aggressive Behaviour, Agitation, AGREE Collaboration, AMSTAR, Anger Irritability and Assault Questionnaire, Antipsychotics Side Effects, Appraisal of Guidelines for Research and Evaluation (AGREE), Aripiprazole, Atypical Antipsychotics, Barratt Impulsiveness Scale, Borderline Personality Disorder (BPD), BPD Severity Index, Buss-Durkee Hostility Inventory, Canadian Agency for Drugs and Technologies in Health (CADTH), Clozapine, Cognitive Impairment, First Generation Antipsychotics (FGA), Haloperidol, HSCL-Anger-Hostility, Mild Cognitive Impairment (MCI), Modified Overt Aggression Scale, National Collaborating Centre for Mental Health, Olanzapine, Overt Aggression Scale Modified, Psychological Symptoms of Dementia (BPSD), Quetiapine, Rapid Response Service (CADTH), Reducing Agitation and Distress, Reducing Inappropriate Use of Antipsychotics in Dementia, Second Generation Antipsychotics (SGA), State-Trait Anger Expression Inventory, Systematic Reviews and Meta-Analyses, Thiothixene, Ward Scale of Impulsive Action, World Federation of Societies of Biological Psychiatry (WFSBP), Zanarini Rating Scale for Borderline Personality Disorder, Ziprasidone
|
Leave a comment
Antipsychotics for Delirium in General Hospitals (International Journal of Geriatric Psychiatry)
Summary This article discusses a prospective observational study, conducted over 1 year at 33 general hospitals in Japan, into the risks and benefits of antipsychotics for older patients with delirium in general hospital settings. Of 2834 patients who developed delirium, 2453 … Continue reading →
Posted in Acute Hospitals, Antipsychotics, Delirium, For Doctors (mostly), For Nurses and Therapists (mostly), For Researchers (mostly), International, Management of Condition, Mental Health, Pharmacological Treatments, Quick Insights
|
Tagged Adverse Drug Events, Adverse Drug Reactions, Adverse Events, Antipsychotic Medication for Delirium, Antipsychotics and Risk of Venous Thromboembolism, Antipsychotics for Delirium, Antipsychotics Side Effects, Antipsychotics-Related Mortality Risks, Atypical Antipsychotics, Care in General Hospitals, Chiba University, Clinical Global Impressions-Improvement Scale, Delirium Etiology Rating Checklist, Department of Psychiatry: Juntendo University Nerima Hospital, Drug Side-Effects, Extrapyramidal Symptoms, Fukushima Medical University, General Hospital Care, General Hospitals, Geriatric Psychiatry, Graduate School of Medicine: Chiba University, Haloperidol, Hiroshima University Hospital, International Journal of Geriatric Psychiatry, International Medical Center of Japan Kounodai Hospital, Japan, Japanese Red Cross Narita Hospital, Juntendo University Nerima Hospital: Tokyo, Juntendo University Urayasu Hospital, Kamiiida Daiichi General Hospital, Kikukawa General Hospital, Koyukai Memorial Hospital, Kurume University School of Medicine, Kyushu University Hospital, Nagano Red Cross Hospital, Nara Hospital Kinki University Faculty of Medicine, National Hospital Organization Osaka National Hospital, Nippon Medical School Musashikosugi Hospital, Osaka Red Cross Hospital, Parenteral Haloperidol, Perospirone, Quetiapine, Reported Adverse Events (RAEs), Risperidone, Serious Adverse Events, Shimane Prefectural Central Hospital, St. Luke's International Hospital, St. Marianna University School of Medicine, Toho University Sakura Medical Center, Tokyo Metropolitan Hiroo Hospital, Tokyo Metropolitan Tama Medical Center
|
Leave a comment
Comparative Mortality Risks from Antipsychotics in Community-Dwelling Older Adults (British Journal of Psychiatry)
Summary A US observational study of 136,393 people, aged 65 years and older, and living in the community, who had recently started taking antipsychotics, was performed to estimate the comparative mortality risks of commonly prescribed antipsychotics. These individuals had recently … Continue reading →
Posted in Antipsychotics, Community Care, For Doctors (mostly), For Nurses and Therapists (mostly), For Researchers (mostly), International, Management of Condition, Pharmacological Treatments, Practical Advice, Quick Insights
|
Tagged Antipsychotic Drugs, Antipsychotic Prescribing in Nursing Homes in the United States, Antipsychotics, Antipsychotics in Elderly People with Dementia, Antipsychotics-Related Mortality Risks, Aripiprazole, Atypical Antipsychotics, Avoidable Mortality, Boston, Brigham and Women's Hospital and Harvard Medical School, British Journal of Psychiatry, College of Physicians and Surgeons: Columbia University, Columbia University, Community-Dwelling Older Adults, Comparative Mortality Risks from Antipsychotics, Department of Medicine: Brigham and Women's Hospital and Harvard Medical School, Department of Pharmacy Practice and Administration: Rutgers University, Department of Psychiatry: Columbia University, Department of Psychiatry: Duke University Medical Center, Department of Psychiatry: Vanderbilt University School of Medicine, Differemtial Antipsychotic-Related Mortality Risks, Differential Risk of Death (Antipsychotic Drugs), Division of Pharmacoepidemiology and Pharmacoeconomics: Brigham and Women's Hospital and Harvard Medical School, Duke University Medical Center, Ernest Mario School of Pharmacy: Rutgers University, Haloperidol, Health Care Policy and Aging Research: Rutgers University, Institute for Health, Institute for Health: Rutgers University, Massachusetts, Mortality Rates, Mortality Statistics, New Brunswick, New Jersey, New York, New York State Psychiatric Institute, Olanzapine, Prescribing of Antipsychotic Drugs For People With Dementia, Preventable Mortality, Quetiapine, Reducing Antipsychotic Medication in Care Homes, Risperidone, Rutgers University, USA, Vanderbilt University School of Medicine, Ziprasidone
|
Leave a comment
Antipsychotics-Related Mortality Risk in Nursing Home Dementia Patients (BMJ / BBC News)
[A version of this item appears in: Dementia: the Latest Evidence Newsletter (RWHT), Volume 2 Issue 8, March 2012]. Summary Some antipsychotic medications increase the risk of death in patients with dementia more than others, according to a US study … Continue reading →
Posted in Acute Hospitals, Age UK, Antipsychotics, Community Care, Dementia Action Alliance, For Doctors (mostly), For Nurses and Therapists (mostly), For Researchers (mostly), In the News, International, Management of Condition, Pharmacological Treatments, Quick Insights, Universal Interest
|
Tagged Antipsychotics-Related Mortality Risks, Aripiprazole, Atypical Antipsychotics, BBC Health News, Behavioral and Psychological Symptoms of Dementia (BPSD), BMJ, BPSD: Behavioral and Psychological Symptoms of Dementia, Differemtial Antipsychotic-Related Mortality Risks, Differential Risk of Death (Antipsychotic Drugs), Haloperidol, Harvard Medical School, Medicaid, Medicare, Minimum Data Set, National Death Index, Nursing Homes, Nursing Homes in the United States, Olanzapine, Psychological Symptoms of Dementia (BPSD), Quetiapine, Risperidone, Ziprasidone
|
Leave a comment
